Evidence map›Paper›PMID 30683973›Full record

ReviewImmunogenetics2019

What to do with HLA-DO/H-2O two decades later?

Robin Welsh, Nianbin Song, Scheherazade Sadegh-Nasseri

Abstract readReview
In one paragraph

Review in Immunogenetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Robin WelshGraduate Program in Immunology and Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Nianbin SongGraduate Program in Immunology and Department of Pathology, Johns Hopkins University, Baltimore, MD, USA.
Scheherazade Sadegh-NasseriGraduate Program in Immunology and Department of Pathology, Johns Hopkins University, Baltimore, MD, USA. ssadegh@jhmi.edu.
Johns Hopkins University · US

Funding

Role of DM in Generation of Immunodominant Epitope(s)R01AI063764 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2006 to 2015
$3.6M
STRUCTURE/BIOLOGY OF SHORT LIVED MHC II LIGAND COMPLEXESR01GM053549 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 1998 to 2007
$1.9M
Understanding the Impacts of HLA-DO in vivoR01AI120634 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2016 to 2019
$1.6M
Molecular Mechanisms of HLA-DO in Antigen ProcessingR21AI101987 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2012 to 2013
$433k
Cell Free System for Identification of MHC Class II Immunodominant EpitopesR56AI091923 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2011 to 2011
$328k
Role of DM in generation in immunodominant epitope(s)R56AI063764 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SADEGH-NASSERI, SCHEHERAZADE · 2005 to 2005
$325k
NIAID NIH HHS R01 AI063764NIAID NIH HHS R01 AI120634NIAID NIH HHS R21 AI101987NIAID NIH HHS R56 AI063764NIAID NIH HHS R56 AI091923NIGMS NIH HHS R01 GM053549
6 · The paper itself

Abstract

The main objective of antigen processing is to orchestrate the selection of immunodominant epitopes for recognition by CD4 T cells. To achieve this, MHC class II molecules have evolved with a flexible peptide-binding groove in need of a bound peptide. Newly synthesized MHC-II molecules bind a class II invariant chain (Ii) upon synthesis and are shuttled to a specialized compartment, where they encounter exogenous antigens. Ii serves multiple functions, one of which is to maintain the shape of the MHC-II groove so that it can readily bind exogenous antigens upon dissociation of the Ii peptide in MHC- II compartment. MIIC contains processing enzymes, one or both accessory molecules, HLA-DM/H2-M (DM) and HLA-DO/H2-O (DO), and optimal denaturing conditions. In a process known as "editing," DM facilitates the dissociation of the invariant chain peptide, CLIP, for exchange with exogenous antigens. Despite the availability of mechanistic insights into DM functions, understanding how DO contributes to epitope selection has proven to be more challenging. The current dogma assumes that DO inhibits DM, whereas an opposing model suggests that DO fine-tunes the epitope selection process. Understanding which of these, or potentially other models of DO function is important, as DO variants have been linked to autoimmunity, cancer, and the generation of broadly neutralizing antibodies to viruses. This review therefore attempts to evaluate experimental evidence in support of these hypotheses, with an emphasis on the less discussed model, and to explore intriguing questions about the importance of DO in biology.

Indexed as

AnimalsAntigen PresentationAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIHLA-D AntigensHumansProtein BindingT-LymphocytesAntigens, Differentiation, B-LymphocyteH-2O antigenHistocompatibility Antigens Class IIHLA-D AntigensHLA-DM antigensHLA-DO antigensinvariant chainAntigen processingH-2OHLA-DMHLA-DOHLA-DRMHC class II

Identifiers

PMID30683973
PMCPMC6377320
OpenAlexW2911404113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.